Oncogenic KRAS signalling in pancreatic cancer. - Wikidata - thesis-toulmin - TriplyDB

Oncogenic KRAS signalling in pancreatic cancer.

Oncogenic KRAS signalling in pancreatic cancer.

http://www.wikidata.org/entity/Q34113460

about

Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment Perspectives in the treatment of pancreatic adenocarcinoma The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma Advances and Challenges on Cancer Cells Reprogramming Using Induced Pluripotent Stem Cells Technologies Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer Targeting the VEGF-C/VEGFR3 axis suppresses Slug-mediated cancer metastasis and stemness via inhibition of KRAS/YAP1 signaling Pancreatic cancer, treatment options, and GI-4000 Regulation of Cellular Identity in Cancer Technologies for controlled, local delivery of siRNA Identification of KCa3.1 Channel as a Novel Regulator of Oxidative Phosphorylation in a Subset of Pancreatic Carcinoma Cell Lines Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions?Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward.Miniaturized Real-Time PCR on a Q3 System for Rapid KRAS Genotyping Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis Utilizing somatic mutation data from numerous studies for cancer research: proof of concept and applications.Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment.Disease pathways at the Rat Genome Database Pathway Portal: genes in context-a network approach to understanding the molecular mechanisms of disease.Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo.Dual roles of NRF2 in tumor prevention and progression: possible implications in cancer treatment Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies.ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer Deregulation of the MiR-193b-KRAS Axis Contributes to Impaired Cell Growth in Pancreatic Cancer Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.Surveying the serologic proteome in a tissue-specific kras(G12D) knockin mouse model of pancreatic cancer.Integrated Genomic Analysis of Pancreatic Ductal Adenocarcinomas Reveals Genomic Rearrangement Events as Significant Drivers of Disease Pancreatic cancer, treatment options, and GI-4000.A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.Multiscale mutation clustering algorithm identifies pan-cancer mutational clusters associated with pathway-level changes in gene expression.Tissue-specific tumorigenesis: context matters.Clinical next generation sequencing to identify actionable aberrations in a phase I program.A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.Amplification-free in situ KRAS point mutation detection at 60 copies per mL in urine in a background of 1000-fold wild type.ATP13A3 and caveolin-1 as potential biomarkers for difluoromethylornithine-based therapies in pancreatic cancers

P2860

Q26740619-FA9D9C5A-03C7-4F2D-ADDB-969C6F187132 Q26797248-7D727CEB-FBCA-42B7-BB93-668D013CC749 Q27021883-BC4D37C9-76F7-421E-96D5-E89E5072B95A Q28069864-69CBA684-844E-4516-A1D5-9A5068DAD74E Q28071879-A40B2C3E-E876-4077-BE08-87180B433D7A Q28073765-6E9202DD-C74A-4415-B88F-A3EB9EA05F1D Q28078716-A43B6D15-FB94-4678-B592-0F59AF32F551 Q28083814-20C1E0C7-A150-49CF-9B74-3E05DF965F3F Q28086849-A20B1E79-DC12-439A-8AB5-F77FD47E7DD0 Q28087657-1582E491-940E-4C0F-B42D-5DCAFD1EFFF1 Q28553394-9E255F85-9BEA-4C82-B9EF-7D2A08D7AFB7 Q30313606-3EF52C70-3C04-46E6-A5BE-7AC887C556C2 Q31012680-C82F32CB-6DAC-4E31-BA09-C545A1E26354 Q33624574-EB56A6BC-7C46-4427-9818-85E2BA8AC85D Q33649652-18622EF8-B2AD-499E-BD85-9486E5C04E91 Q33730022-705E97DF-B1B8-4BBD-8664-4995EE81B7FF Q33754779-2039DA2A-5959-4C5C-99EC-E75D5628C9A2 Q33835909-EE7236D6-16B0-4BAD-A3E8-8E33E61F256C Q33838679-60274DA2-AFF5-48A9-ABAC-020A4300ECF1 Q34312452-68AC955D-F34B-4A19-8D24-A6C2159B9F0B Q34518484-855162D0-BD5A-4FD2-803E-C2BA8A143FF1 Q35118710-482471A4-F0CD-4021-985C-1B06C20377AC Q35136815-3548CB0D-F2A6-40D2-A5FD-8BAACBBB4DEB Q35578938-964FC7C0-A1F6-4C78-8AF0-D6110D8005D9 Q35612378-6CDA58E2-A6E0-4658-AF71-96AFB43E0346 Q35801876-034AA8E6-0E33-4043-B5B5-26FEE3D61FFA Q35842473-7B8E3673-3AFC-4B3E-9E77-D80F1F9320F5 Q35871175-D2F8A250-4CE9-4790-824D-27EEAC17972B Q35887099-70F98EF0-B32C-47F6-8361-47E080385436 Q36000183-9E6EC47B-50FB-4BD4-9BA2-BBBE7C685789 Q36092550-FC1E0B61-3E7A-40F6-B9F0-73CFE0963CAA Q36103351-9D41CE8E-DDE0-414C-8D8F-A49937FE6296 Q36111466-1B42CB30-93AE-4204-A5FB-BC6B3D8865AC Q36140634-FD2DAEC6-BBFB-4625-B8EC-DEAEC28FB487 Q36272766-C41DA865-24DE-4A3D-8A71-2836904AAB7B Q36296335-2C78B7FD-18AA-4F9C-A54F-263DEF113B03 Q36299589-DB57765F-8C1D-46A3-BF0E-FF317E9C6255 Q36437111-EEBEDBF2-F3AA-4F0D-B168-3B21C6C9A8CF Q36563555-4DC54661-E817-483C-9CD3-B85E98F6CBB4 Q37077387-29C65A78-0348-4565-8525-1075CE2FD4F8

P2860

Oncogenic KRAS signalling in pancreatic cancer.

http://www.wikidata.org/entity/Q34113460

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Oncogenic KRAS signalling in pancreatic cancer.

@ast

Oncogenic KRAS signalling in pancreatic cancer.

@en

Oncogenic KRAS signalling in pancreatic cancer.

@nl

type

label

Oncogenic KRAS signalling in pancreatic cancer.

@ast

Oncogenic KRAS signalling in pancreatic cancer.

@en

Oncogenic KRAS signalling in pancreatic cancer.

@nl

prefLabel

Oncogenic KRAS signalling in pancreatic cancer.

@ast

Oncogenic KRAS signalling in pancreatic cancer.

@en

Oncogenic KRAS signalling in pancreatic cancer.

@nl

P1433

Q34113460-82132BC3-9255-4535-98FF-31018F735341

P1476

Q34113460-3010A8E8-BE6A-4B2C-BD21-B502B5D5BDFC

P2093

Q34113460-1A78EBF0-99B1-4880-81AC-F40FC4DEB83A

Q34113460-287DA3BB-F23D-4ADE-9358-222939B56637

Q34113460-96F0F047-5717-40A9-AF85-C7FB540353EA

P275

Q34113460-1D5272B3-C9D7-4F99-A6CA-70432FAC2190

P2860

Q34113460-01E18112-5AA8-47DB-AEE1-B5F51FB076B5

Q34113460-01EC11F5-C0F7-4B76-8640-C6FFA97F210F

Q34113460-0C3EE8C2-0A00-4D77-885B-FC7DF241FB56

Q34113460-1267325F-AB6F-44A1-9019-8960527652CF

Q34113460-14D99781-2DF7-45E9-A569-9B04092CA06D

Q34113460-198D6906-A4BA-4EED-A4D9-8C8A7153F872

Q34113460-1C86F3A6-CFD2-451C-8EA5-E2DE872A02C8

Q34113460-1D8F83DC-DC1E-4886-BAD8-4FF8B15A9ABA

Q34113460-2098E1CF-C4F6-4025-9304-3352743F9918

Q34113460-20F7E7FC-3CE1-48B9-A92A-F86B52761FFE

P2888

Q34113460-8828A235-D411-4AB0-95C3-8226931E966E

P304

Q34113460-58E897E2-EC11-462A-8554-E49CB6EACC90

P31

Q34113460-9497432F-E369-4290-94DB-B7C008F49A79

Q34113460-DBEDC660-00FF-492C-AE7C-2C5060F0BAC6

P356

Q34113460-675987FD-EB0F-4BD6-B2C2-1E774B747624

P407

Q34113460-DBEBBB53-44C6-4DA5-9C0A-A5826D3A7D4A

P433

Q34113460-1F7829D4-6A99-4983-863B-95DB104A063E

P478

Q34113460-260F3F66-75F2-42EF-AC5D-9C7C30EB52E8

P50

Q34113460-656F4AD3-A519-4906-84F0-7570418E9867

P5008

Q34113460-E6C0BB64-F2B9-4857-8523-44CBFC4CD991

P577

Q34113460-8DD2A01D-8112-498C-AFAE-FF559B1FA08F

Q34113460-8EB08D14-6728-45ED-BBA3-88EA2482D080

P5875

Q34113460-7AAC6028-DD78-4A71-A0C0-71A937571B45

P6179

Q34113460-1F3F9BFB-04FA-482C-B80A-C442475BBF4C

P698

Q34113460-F6D1DBF6-8518-4FB3-8A64-46AA9D472D99

P921

Q34113460-0B4AEE90-B52D-4A3C-85DF-2E1AADC342A3

Q34113460-26E90AE7-6D90-4F95-A697-E2EE2A9015DC

Q34113460-30BA0F24-1357-480B-B4F8-5478BBA9722C

Q34113460-72935CA1-6624-47B7-9CC0-FDB6C42005B7

Q34113460-7CFEA2E1-9917-497E-B984-5BB48F3F5E0F

Q34113460-83FA8C3C-0827-4757-820B-85BDFA9B05F3

Q34113460-DA2BDC51-55AC-4459-B116-C56E44654C04

P932

Q34113460-D25E6F76-42BD-49C0-9EA2-9690B23CCA42

P356

P1433

British Journal of Cancer

P1476

Oncogenic KRAS signalling in pancreatic cancer.

@en

P2093

D Saur

http://www.w3.org/2001/XMLSchema#string

G Schneider

http://www.w3.org/2001/XMLSchema#string

S Eser

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

P2860

Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Exploiting inflammation for therapeutic gain in pancreatic cancer

Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity

Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

P2888

P304

817-822

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2014.215

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Angelika Schnieke

P5008

P577

2014-04-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2014-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261800696

http://www.w3.org/2001/XMLSchema#string

P6179

1024132312

http://www.w3.org/2001/XMLSchema#string

P698

24755884

http://www.w3.org/2001/XMLSchema#string

P921

pancreatic cancer

transport protein

proto-oncogene proteins

neoplasm proteins

pancreatic neoplasm

P932

4150259

http://www.w3.org/2001/XMLSchema#string